[Benralizumab: Targeting the IL-5 Receptor in Severe Eosinophilic Asthma].

Leuppi, Jörg D; Schmid-Grendelmeier, Peter; Rothe, Thomas; von Garnier, Christophe; Simon, Hans-Uwe; Schuoler, Claudio; Pendl, Gunther; Solèr, Markus (2019). [Benralizumab: Targeting the IL-5 Receptor in Severe Eosinophilic Asthma]. Praxis, 108(7), pp. 469-476. Hogrefe 10.1024/1661-8157/a003222

Text 1661-8157_a003222.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (2MB)

Benralizumab: Targeting the IL-5 Receptor in Severe Eosinophilic Asthma For patients with difficult-to-control, severe bronchial asthma, highly effective, targeted treatment options are available in addition to inhaled medication. In the presence of eosinophilia, inhibition of the interleukin-5 (IL‑5) axis with specific monoclonal antibodies promises to be an effective alternative to continuous systemic steroid therapy with few side effects. This review summarizes the data on benralizumab, a specific antibody against the IL-5 receptor alpha preventing receptor stimulation by IL-5 and activating a NK-cell mediated cytotoxic reaction with apoptosis of eosinophils. The s.c.-application of benralizumab leads within days to a virtually complete depletion of blood eosinophils with consecutive improvement in lung function and stabilization of asthma. For selected severe asthmatics, this is a promising therapy option.

Interest & Impact

Downloads

5 since deposited on 06 Aug 2019
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item